# Cerevast Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerevast-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Redmond, US
- Website: www.cerevast.com
- Total disclosed funding: $5M
- Latest round: Series C (Nov 24, 2014)
- Investors on record: 1

## About

Cerevast Therapeutics specializes in innovative healthcare solutions aimed at treating retinal vein occlusion and stroke through advanced ultrasound technologies that enhance therapeutic outcomes for patients.Cerevast Therapeutics, Inc. is focused on developing advanced ultrasound therapies. Founded in 2009 and headquartered in Redmond, US, the company has engaged in a total of 9 deals, with its most recent funding round occurring in March 2015. During this round, Cerevast raised USD 11.38 mn. The current CEO is Bradford Zakes.Cerevast's primary focus is on innovative healthcare solutions aimed at treating conditions related to retinal vein occlusion (RVO) and stroke. The company's core product offerings include microsphere-mediated ophthalmic ultrasound and transcranial ultrasound therapies, which leverage advanced ultrasound technology to enhance thrombolysis and neuromodulation. These solutions are designed to improve patient outcomes by targeting specific areas within the body to promote healing and restore health. The end users of these services primarily consist of healthcare providers and medical institutions that serve patients suffering from ocular and neurological conditions. Cerevast's products are marketed predominantly in North America and Europe, catering to a diverse client base that includes hospitals, outpatient clinics, and specialized treatment centers.Cerevast generates revenue through a structured business model that encompasses both direct sales and strategic partnerships with healthcare providers. Transactions typically involve the selling of proprietary medical devices and therapies, with a focus on securing contracts with hospitals and clinics that incorporate these innovative solutions into their treatment protocols. The pricing structure for Cerevast's services is aligned with the value provided through improved patient outcomes and operational efficiencies. Flagship offerings, such as the microsphere-mediated ophthalmic ultrasound, are marketed under trademarked names, providing the company with branding leverage in the competitive healthcare marketplace. Revenue streams are bolstered by ongoing collaborations and partnerships that enhance the distribution and accessibility of their products across various geographical markets.Cerevast Therapeutics plans to leverage its recent funding of USD 11.38 mn raised in March 2015 to develop new products and enhance existing therapies. The company is focusing on expanding into new markets, particularly in Europe and Asia, by 2025. The funding will primarily support product development and market entry efforts to increase their presence in these targeted regions.

## Funding rounds

- Series C, Nov 24, 2014, $5M — Haiyin Capital

## Investors

- Haiyin Capital (https://capitalatlas.ai/funds/haiyin-capital) — Series C